Predict your next investment

Angel Investor (Group)
bostonharborangels.com

See what CB Insights has to offer

Investments

151

Portfolio Exits

17

Partners & Customers

1

About Boston Harbor Angels

Boston Harbor Angels is a group of business leaders interested in investing in growth, early stage companies. The group was formed in February 2004 and since then has made a number of investments in companies in medical devices, IT, consumer products, business products, specialty materials, Internet, aviation, etc. The group's focus is on early stage companies usually looking to raise $250K to $1.5M, where Boston Harbor can fund a portion of the round and then syndicate the deal with other angel groups or early stage venture funds. The stage of the company should be close to commercialization, while the company should have a clear and defensible competitive advantage. The firm looks for capital efficient businesses, which can reach profitability with less than $5M of equity investment and provide at least 10X return on the investment within 5 years.

Boston Harbor Angels Headquarter Location

Boston, Massachusetts,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Boston Harbor Angels News

Ziad Moukheiber, CEO of Boston Harbor Angels Joins the Board of Distributed Ledger FinTech Startup Tunnel

Mar 19, 2019

0 Message : Tunnel offers enterprise cloud-based distributed ledger solutions. Tunnel a FinTech startup delivering a unique distributed ledger technology (DLT) and payment network, previously closed a seed round of funding lead by prominent angel investment firm Boston Harbor Angels with Colony Hills Capital, EQX Fund, Wilmington Investor Network and Tomahawk Group all participating. Ziad Moukheiber, CEO of Boston Harbor Angels, led the investment round and recently joined the Board of Directors at Tunnel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190319005642/en/ Tunnel's Board of Directors - Tunnel COO Neil Ratna (left), Tunnel CEO Frank Makrides (middle) & Boston Harbor Angels CEO Ziad Moukheiber (right). (Photo: Business Wire) As a startup in Boston’s FinTech scene, Tunnel is modernizing the several decades old payment infrastructure used by banks, financial institutions, businesses and consumers. Tunnel brings to market a very disruptive technology focused on providing a next generation real-time, scalable and secure payments on the cloud powered by a patent-pending DLT engine. Tunnel provides seamless integration with open APIs allowing businesses to facilitate B2B, B2C and P2P payments all while keeping their current user experience intact through application integration or white label offerings. For the first time a business can receive a payment in real-time, at ultra-low cost and with confidence. By taking on traditional business payment transaction fee based models Tunnel can open the door for microtransactions as small as a penny to very large ($1M+) secure value transfers. This opportunity opens Tunnel to trillions in potential value transfer in need of a solution. About Tunnel Boston-based Tunnel’s mission is to modernize the payments technology infrastructure as well as the business model of the the global payments ecosystem. Tunnel is a Boston-based FinTech startup pioneering a uniquely designed, distributed ledger technology (DLT) with solutions for scalable real-time payments, identity, directory and APIs. Tunnel is a permissioned network for banks and businesses. Tunnel helps the bottom line of businesses, brings advanced security, reduces fraud, and can scale to the needs of businesses and consumers. Tunnel offers seamless integration to existing business applications with a turnkey cloud-based solution. For more information, visit www.tunnel.money View source version on businesswire.com: https://www.businesswire.com/news/home/20190319005642/en/ © Business Wire 2019

Boston Harbor Angels Investments

151 Investments

Boston Harbor Angels has made 151 investments. Their latest investment was in S'More as part of their Seed VC - II on January 1, 2021.

CBI Logo

Boston Harbor Angels Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/26/2021

Seed VC - II

S'More

$2.1M

Yes

7

12/10/2020

Series A

Astrocyte Pharmaceuticals

$6M

No

2

9/26/2017

Series B - II

BIOARRAY Genetics

$4M

No

6

3/24/2017

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

4/29/2015

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/26/2021

12/10/2020

9/26/2017

3/24/2017

4/29/2015

Round

Seed VC - II

Series A

Series B - II

Seed VC

Series A

Company

S'More

Astrocyte Pharmaceuticals

BIOARRAY Genetics

Subscribe to see more

Subscribe to see more

Amount

$2.1M

$6M

$4M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

7

2

6

10

10

Boston Harbor Angels Portfolio Exits

17 Portfolio Exits

Boston Harbor Angels has 17 portfolio exits. Their latest portfolio exit was Chronix Biomedical on February 04, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/4/2021

Acquired

4

8/26/2019

Acquired

3

8/21/2019

Acquired

$991

Acquirer

1

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

2/4/2021

8/26/2019

8/21/2019

00/00/0000

00/00/0000

Exit

Acquired

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

Acquirer

Acquirer

Subscribe to see more

Subscribe to see more

Sources

4

3

1

10

10

Boston Harbor Angels Partners & Customers

1 Partners and customers

Boston Harbor Angels has 1 strategic partners and customers. Boston Harbor Angels recently partnered with Boehringer Ingelheim, and Abexxa Biologics on December 12, 2017.

Date

Type

Business Partner

Country

News Snippet

Sources

12/13/2017

Partner

Boehringer Ingelheim, and Abexxa Biologics

Germany, and United States

Boehringer Ingelheim highlights progress of immuno-oncology collaborations – Boston Harbor Angels

It has also partnered with Siamab Therapeutics to identify anticancer therapeutics that target tumour-associated carbohydrate antigens , while another collaboration with AbeXXa Biologics has been formed to identify new selective molecular targets for cancer from the thousands of proteins found inside tumour cells .

1

Date

12/13/2017

Type

Partner

Business Partner

Boehringer Ingelheim, and Abexxa Biologics

Country

Germany, and United States

News Snippet

Boehringer Ingelheim highlights progress of immuno-oncology collaborations – Boston Harbor Angels

It has also partnered with Siamab Therapeutics to identify anticancer therapeutics that target tumour-associated carbohydrate antigens , while another collaboration with AbeXXa Biologics has been formed to identify new selective molecular targets for cancer from the thousands of proteins found inside tumour cells .

Sources

1

Boston Harbor Angels Team

3 Team Members

Boston Harbor Angels has 3 team members, including current President, Michael Williams.

Name

Work History

Title

Status

Michael Williams

President

Current

Boris Batchvarov

Managing Director

Current

Aleksandar Mollov

Managing Director

Former

Name

Michael Williams

Boris Batchvarov

Aleksandar Mollov

Work History

Title

President

Managing Director

Managing Director

Status

Current

Current

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.